Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies
- DOI
- 10.3389/fimmu.2026.1811816
- Published
- 2026-05-20
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1811816,
title = {Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies},
author = {Jiashun Li and Ainikaer Abulaiti and Deyu Li and Yan Zhao and Paerhati Wahafu and Maerdan Maimaitiming and Shi Qiu and Yuxiang Zhang and Yaqin An and Wenxing Wang and Liangquan Shi and Maihemuti Yakufu and Li Shu and Guohua Li and Zhen Liu},
year = {2026},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2026.1811816},
url = {https://doi.org/10.3389/fimmu.2026.1811816}
}RIS
TY - JOUR TI - Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies AU - Jiashun Li AU - Ainikaer Abulaiti AU - Deyu Li AU - Yan Zhao AU - Paerhati Wahafu AU - Maerdan Maimaitiming AU - Shi Qiu AU - Yuxiang Zhang AU - Yaqin An AU - Wenxing Wang AU - Liangquan Shi AU - Maihemuti Yakufu AU - Li Shu AU - Guohua Li AU - Zhen Liu PY - 2026 JO - Frontiers in Immunology DO - 10.3389/fimmu.2026.1811816 UR - https://doi.org/10.3389/fimmu.2026.1811816 ER -
APA
Li, J., Abulaiti, A., Li, D., Zhao, Y., Wahafu, P., Maimaitiming, M., Qiu, S., Zhang, Y., An, Y., Wang, W., Shi, L., Yakufu, M., Shu, L., Li, G., & Liu, Z. (2026). Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1811816
Source records
- crossref · retrieved 2026-11-10T18:59:36.373Z